PARAMUS, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, is pleased to announce its successful scientific Advisory Board meeting held during the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. Led by Starton’s Scientific Board members and Chief Medical Officer, the meeting was attended by recognized experts and key opinion leaders in the field of oncology and yielded significant insights and outcomes that will shape the Company’s research and development efforts in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM).

Link:
Starton Therapeutics Strengthens Clinical Development Strategy Following Successful Scientific Advisory Board Meeting at ASCO 2024